# Eli Lilly and Company (LLY)

Source: https://www.quantisnow.com/company/LLY
Generated: 2026-11-22T20:32:04.419Z

- Ticker: LLY
- Exchange: NYSE
- Sector: Health Care
- Industry: Biotechnology: Pharmaceutical Preparations
- SEC CIK: 0000059478
- Website: lilly.com

## About

Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceuticals worldwide. It offers Baqsimi for severe hypoglycemia; Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500, and Lyumjev for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company also provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+ and HER2- metastatic breast cancer. In addition, it offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis. Further, the company Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; Reyvow for migraine; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Additionally, it Bamlanivimab and etesevimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. Eli Lilly and Company has collaborations with Incyte Corporation; Pfizer Inc.; AC Immune SA; Centrexion Therapeutics Corporation; ImmuNext, Inc.; Avidity Biosciences, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; and MiNA Therapeutics Limited. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.

## Latest LLY news and filings

- 2026-11-19 05:26 UTC [Promo] [Gold, Silver and Crude Slide Hard as Volatility Jumps on the Week](https://www.quantisnow.com/insight/gold-silver-and-crude-slide-hard-as-volatility-jumps-on-6799635)
- 2026-11-17 21:50 UTC [SEC Form 4] [Director Jamere Jackson was granted 168 shares, increasing direct ownership by 2% to 9,861 units (SEC Form 4)](https://www.quantisnow.com/insight/director-jamere-jackson-was-granted-168-shares-increasing-direct-ownership-6797166)
- 2026-11-17 21:19 UTC [SEC Form 4] [Director Jon R Moeller was granted 168 shares, increasing direct ownership by 55% to 473 units (SEC Form 4)](https://www.quantisnow.com/insight/director-jon-r-moeller-was-granted-168-shares-increasing-direct-6796825)
- 2026-11-17 21:18 UTC [SEC Form 4] [Director William G Kaelin Jr was granted 168 shares, increasing direct ownership by 0.76% to 22,139 units (SEC Form 4)](https://www.quantisnow.com/insight/director-william-g-kaelin-jr-was-granted-168-shares-increasing-6796819)
- 2026-11-17 21:17 UTC [SEC Form 4] [Director Kimberly H Johnson was granted 168 shares, increasing direct ownership by 5% to 3,452 units (SEC Form 4)](https://www.quantisnow.com/insight/director-kimberly-h-johnson-was-granted-168-shares-increasing-direct-6796800)
- 2026-11-17 21:15 UTC [SEC Form 4] [Director Carolyn R Bertozzi was granted 178 shares, increasing direct ownership by 9% to 2,178 units (SEC Form 4)](https://www.quantisnow.com/insight/director-carolyn-r-bertozzi-was-granted-178-shares-increasing-direct-6796781)
- 2026-11-17 21:14 UTC [SEC Form 4] [Director Katherine Baicker was granted 168 shares, increasing direct ownership by 0.71% to 23,815 units (SEC Form 4)](https://www.quantisnow.com/insight/director-katherine-baicker-was-granted-168-shares-increasing-direct-ownership-6796752)
- 2026-11-17 21:14 UTC [SEC Form 4] [Director Mary Lynne Hedley was granted 168 shares, increasing direct ownership by 7% to 2,430 units (SEC Form 4)](https://www.quantisnow.com/insight/director-mary-lynne-hedley-was-granted-168-shares-increasing-direct-6796737)
- 2026-11-17 21:13 UTC [SEC Form 4] [Director Gabrielle Sulzberger was granted 171 shares, increasing direct ownership by 6% to 3,188 units (SEC Form 4)](https://www.quantisnow.com/insight/director-gabrielle-sulzberger-was-granted-171-shares-increasing-direct-ownership-6796729)
- 2026-11-17 21:12 UTC [SEC Form 4] [Director Juan R Luciano was granted 179 shares, increasing direct ownership by 1% to 17,148 units (SEC Form 4)](https://www.quantisnow.com/insight/director-juan-r-luciano-was-granted-179-shares-increasing-direct-6796722)
- 2026-11-17 21:11 UTC [SEC Form 4] [Director J Erik Fyrwald was granted 175 shares, increasing direct ownership by 0.23% to 75,719 units (SEC Form 4)](https://www.quantisnow.com/insight/director-j-erik-fyrwald-was-granted-175-shares-increasing-direct-6796716)
- 2026-11-17 21:10 UTC [SEC Form 4] [Director Ralph Alvarez was granted 176 shares, increasing direct ownership by 0.32% to 56,025 units (SEC Form 4)](https://www.quantisnow.com/insight/director-ralph-alvarez-was-granted-176-shares-increasing-direct-ownership-6796707)
- 2026-11-17 19:52 UTC [FDA Approval for RETEVMO issued to ELI LILLY AND CO](https://www.quantisnow.com/insight/fda-approval-for-retevmo-issued-to-eli-lilly-and-co-6796351)
- 2026-11-17 19:52 UTC [FDA Approval for RETEVMO issued to ELI LILLY AND CO](https://www.quantisnow.com/insight/fda-approval-for-retevmo-issued-to-eli-lilly-and-co-6796350)
- 2026-11-17 00:23 UTC [Promo] [Stocks Carry Weekly Gains Into a Wall of Chart Resistance as Volatility Cools](https://www.quantisnow.com/insight/stocks-carry-weekly-gains-into-a-wall-of-chart-resistance-6795176)
- 2026-11-14 17:01 UTC [Lilly to present new data across Zepbound, Foundayo, EloraTZP and retatrutide at ObesityWeek 2026, moving obesity care beyond the scale](https://www.quantisnow.com/insight/lilly-to-present-new-data-across-zepbound-foundayo-eloratzp-and-6791839)
- 2026-11-13 20:47 UTC [Promo] [Weekly Gains Hold Up Despite a Friday Slide as Chips Lead and Yields Climb](https://www.quantisnow.com/insight/weekly-gains-hold-up-despite-a-friday-slide-as-chips-6790310)
- 2026-11-12 20:30 UTC [Lilly breaks ground in Pennsylvania's Lehigh Valley on a $3.5 billion site to make next-generation obesity medicines, the latest of 10 new U.S. sites since 2020](https://www.quantisnow.com/insight/lilly-breaks-ground-in-pennsylvanias-lehigh-valley-on-a-35-6787422)
- 2026-11-11 18:30 UTC [Promo] [Nasdaq Jumps Over 4% This Week as Chip Names Drive a Sharp Midweek Rally](https://www.quantisnow.com/insight/nasdaq-jumps-over-4-this-week-as-chip-names-drive-6785413)
- 2026-11-11 14:45 UTC [New Phase 3b data on Lilly's Taltz (ixekizumab) and Zepbound (tirzepatide) used together showed improved and durable efficacy, patient-reported and metabolic outcomes at one year in adults with psoriatic arthritis and obesity](https://www.quantisnow.com/insight/new-phase-3b-data-on-lillys-taltz-ixekizumab-and-zepbound-6785357)
- 2026-11-10 21:38 UTC [SEC Form 4] [EVP & President, LLY Int'l Jonsson Patrik gifted 704 shares, decreasing direct ownership by 1% to 53,443 units (SEC Form 4)](https://www.quantisnow.com/insight/evp-president-lly-intl-jonsson-patrik-gifted-704-shares-decreasing-6784452)
- 2026-11-10 13:00 UTC [Life doesn't slow down, and Foundayo™ (orforglipron) patient Leanne Morgan is done waiting](https://www.quantisnow.com/insight/life-doesnt-slow-down-and-foundayo-orforglipron-patient-leanne-morgan-6783006)
- 2026-11-09 16:08 UTC [Dividends] [Indices Hunt for Support After Steep Weekly Losses as Volatility Gauge Stays Elevated](https://www.quantisnow.com/insight/indices-hunt-for-support-after-steep-weekly-losses-as-volatility-6780770)
- 2026-11-09 14:30 UTC [Lilly's Foundayo (orforglipron) significantly reduced obstructive sleep apnea severity, reinforcing its potential to improve health beyond weight loss](https://www.quantisnow.com/insight/lillys-foundayo-orforglipron-significantly-reduced-obstructive-sleep-apnea-severity-reinforcing-6780693)
- 2026-11-09 13:00 UTC [Gabelli Releases Agenda for 8th Annual Healthcare Symposium](https://www.quantisnow.com/insight/gabelli-releases-agenda-for-8th-annual-healthcare-symposium-6780377)
- 2026-11-06 11:47 UTC [Lilly and Hims & Hers expand access to FDA-approved Lilly medicines](https://www.quantisnow.com/insight/lilly-and-hims-hers-expand-access-to-fda-approved-lilly-medicines-6777857)
- 2026-11-05 11:45 UTC [Lilly to showcase new retatrutide, Taltz (ixekizumab) and Zepbound (tirzepatide) data at ACR Convergence 2026, advancing science at the intersection of rheumatologic conditions and obesity](https://www.quantisnow.com/insight/lilly-to-showcase-new-retatrutide-taltz-ixekizumab-and-zepbound-tirzepatide-6774288)
- 2026-11-04 21:17 UTC [SEC Form 4] [President, Chair, and CEO Ricks David A gifted 23,538 shares (SEC Form 4)](https://www.quantisnow.com/insight/president-chair-and-ceo-ricks-david-a-gifted-23538-shares-6772903)
- 2026-11-04 12:00 UTC [Dividends] [Treasury's Refunding Details Are Up Next as Five Large Companies Report Higher Revenue](https://www.quantisnow.com/insight/treasurys-refunding-details-are-up-next-as-five-large-companies-6771224)
- 2026-11-03 21:15 UTC [SEC Form 4] [EVP, CS&PO & Pres. LRL Skovronsky Daniel gifted 119 shares, decreasing direct ownership by 0.07% to 159,953 units (SEC Form 4)](https://www.quantisnow.com/insight/evp-cspo-pres-lrl-skovronsky-daniel-gifted-119-shares-decreasing-6769854)
- 2026-11-03 21:14 UTC [SEC Form 4] [EVP, GC & Secretary Hakim Anat sold $7,012,600 worth of shares (5,000 units at $1,402.52) as part of a pre-agreed trading plan (SEC Form 4)](https://www.quantisnow.com/insight/evp-gc-secretary-hakim-anat-sold-7012600-worth-of-shares-6769810)
- 2026-11-03 21:14 UTC [SEC Form 4] [EVP & CFO Montarce Lucas converted options into 1,610 shares and covered exercise/tax liability with 678 shares, increasing direct ownership by 6% to 17,191 units (SEC Form 4)](https://www.quantisnow.com/insight/evp-cfo-montarce-lucas-converted-options-into-1610-shares-and-6769787)
- 2026-11-03 21:14 UTC [SEC Form 4] [EVP & Pres., Mfg. Operations Hernandez Edgardo converted options into 2,530 shares and covered exercise/tax liability with 1,123 shares, increasing direct ownership by 3% to 47,490 units (SEC Form 4)](https://www.quantisnow.com/insight/evp-pres-mfg-operations-hernandez-edgardo-converted-options-into-2530-6769745)
- 2026-11-03 21:13 UTC [SEC Form 4] [EVP, Chief People Officer Dozier Eric converted options into 2,300 shares and covered exercise/tax liability with 1,019 shares, increasing direct ownership by 9% to 15,520 units (SEC Form 4)](https://www.quantisnow.com/insight/evp-chief-people-officer-dozier-eric-converted-options-into-2300-6769744)
- 2026-11-03 21:12 UTC [SEC Form 4] [EVP & President, Card Met Hlth Custer Kenneth L. converted options into 3,220 shares and covered exercise/tax liability with 1,425 shares, increasing direct ownership by 18% to 11,935 units (SEC Form 4)](https://www.quantisnow.com/insight/evp-president-card-met-hlth-custer-kenneth-l-converted-options-6769727)
- 2026-11-03 21:12 UTC [SEC Form 4] [EVP,  President LLY Imm Brown Adrienne S converted options into 2,530 shares and covered exercise/tax liability with 1,099 shares, increasing direct ownership by 17% to 9,894 units (SEC Form 4)](https://www.quantisnow.com/insight/evp-president-lly-imm-brown-adrienne-s-converted-options-into-6769720)
- 2026-10-29 15:35 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by Eli Lilly and Company](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-eli-lilly-and-company-6763084)
- 2026-10-29 11:03 UTC [SEC Form 8-K] [SEC Form 8-K filed by Eli Lilly and Company](https://www.quantisnow.com/insight/sec-form-8-k-filed-by-eli-lilly-and-company-6762422)
- 2026-10-29 10:45 UTC [Earnings] [Lilly reports third-quarter 2026 financial results, raises full-year guidance and highlights regulatory progress across the portfolio](https://www.quantisnow.com/insight/lilly-reports-third-quarter-2026-financial-results-raises-full-year-guidance-and-6762251)
- 2026-10-28 10:45 UTC [Lilly's retatrutide delivered greater A1C reduction and more than double the weight loss of Ozempic's highest approved dose in head-to-head trial](https://www.quantisnow.com/insight/lillys-retatrutide-delivered-greater-a1c-reduction-and-more-than-double-6760348)

## More

- Live page with ratings, short volume, options and peers: https://www.quantisnow.com/company/LLY
- Earnings history: https://www.quantisnow.com/earnings/LLY
- Dividend history: https://www.quantisnow.com/dividends/LLY
- Insider transactions: https://www.quantisnow.com/insiders/LLY
- Options chain: https://www.quantisnow.com/options/LLY
- SEC 8-K filings only: https://www.quantisnow.com/company/LLY/8-k
- RSS and alerts for LLY: https://www.quantisnow.com/docs/rss-feeds.md
